Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteLenacapavir is a twice-yearly HIV prevention injection, but a strong trial result does not mean everyone can get it. Access depends on local approval and registration, funded supply, testing and injection services, and whether those services reach people who could benefit.
What lenacapavir does—and what the trial results mean
Lenacapavir (LEN) is a long-acting antiretroviral used as pre-exposure prophylaxis, or PrEP, to help prevent HIV. In the United States it is marketed as Yeztugo. It is administered by injection every six months and is intended for people who do not have HIV and want prevention before possible exposure.
In its 2025 review of the PURPOSE 1 and PURPOSE 2 randomized trials, the US Centers for Disease Control and Prevention (CDC) reported 100% efficacy among female participants and 96% in a primarily male trial population over 52 weeks, compared with estimated background HIV incidence. Those are findings from specific trial populations and a defined follow-up period—not a promise of zero risk for every individual, nor a head-to-head comparison with every other PrEP medicine. CDC reported no significant safety concerns in the trials; injection-site reactions were the most common adverse events and were generally mild to moderate.
The scale of HIV makes additional prevention choices important: the World Health Organization (WHO) reported 1.3 million new infections in 2024 and 40.8 million people living with HIV at the end of that year, 65% of them in the WHO African Region. WHO Director-General Tedros Adhanom Ghebreyesus described lenacapavir as “the next best thing” while noting that an HIV vaccine remains elusive; his statement referred to a medicine shown in trials to prevent almost all infections among people at risk, not to universal effectiveness in every setting.
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
What approvals and recommendations have—and have not—changed
The US Food and Drug Administration approved injectable lenacapavir for PrEP on June 18, 2025. That approval applies in the United States; it does not itself authorize use or ensure supply in other countries. On July 14, 2025, WHO recommended lenacapavir as an additional PrEP choice within combination HIV prevention. CDC strongly recommends twice-yearly injectable lenacapavir as an option for people weighing at least 35 kg who would benefit from PrEP.
WHO’s recommendation places LEN alongside other options—including oral PrEP, injectable cabotegravir and the dapivirine vaginal ring—rather than making it the only or preferred choice for everyone. Condoms and other prevention measures remain part of combination prevention. The best option depends on a person’s circumstances and preferences, as well as what is actually available through local health services.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
A recommendation is not the same as a national registration, a procurement contract, stocked product or an operating clinic service. WHO said in July 2025 that access outside clinical trials was still limited and called for governments and partners to integrate rollout into national combination-prevention programs.
Where rollout had reached by 2026
By April 14, 2026, the Global Fund reported initial deliveries to nine African countries. It said rollout had begun in six; the other three early recipients were expected to start soon. The distinction matters: a delivery to a country is not proof that the medicine is available to every eligible person there.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
| Status in the Global Fund update of April 14, 2026 | Countries |
|---|---|
| Initial deliveries reported | Eswatini, Kenya, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia and Zimbabwe |
| Rollout reported as begun | Eswatini, Kenya, Lesotho, Nigeria, Zambia and Zimbabwe |
| Initial deliveries received; rollout expected to commence soon | Mozambique, South Africa and Uganda |
The Global Fund also extended introduction support to 12 additional countries: Benin, Botswana, the Dominican Republic, Fiji, Georgia, Haiti, Honduras, Indonesia, Morocco, Papua New Guinea, Rwanda and Thailand. Support or inclusion in an introduction plan should not be read as confirmation that patients in those countries could already obtain lenacapavir.
Early program data cited by the Global Fund indicated particularly strong uptake among pregnant and breastfeeding women, adolescent girls and young women, and people using PrEP for the first time. The organization said the data were still being consolidated as programs expanded, so they describe early implementation rather than a complete picture of demand or access.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
Why generic supply does not immediately mean universal access
A UNAIDS background paper dated December 2025 recorded two generic-manufacturer agreements at US$40 per person per year, plus an additional US$15 oral loading dose. These were agreement milestones reported in the paper, not a universal patient price, a guarantee of reimbursement, or evidence that the product was available at that price in every country. The same paper recorded WHO prequalification of oral and injectable lenacapavir in October 2025, and registrations in South Africa and Zambia in October and November 2025, respectively.
In an update dated September 24, 2026, the Global Fund said initial generic supply was anticipated in late 2026 and broader availability was expected in 2027. These are forecasts, not completed supply milestones. The organization emphasized that country registration is critical to matching supply with demand and described manufacturer submissions and use of its Expert Review Panel procurement route. Even when a product is prequalified or a manufacturer can supply it, country authorization, purchasing, delivery and service readiness still affect whether a person can receive it.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
- Regulatory status: Has the relevant national authority approved and registered the product for PrEP?
- Financing and procurement: Has a government, donor or health program funded orders and arranged supply? An international price agreement does not establish what a patient will pay locally.
- Service capacity: Can local providers offer the required HIV testing, prescribe PrEP and administer follow-up injections?
- Equitable reach: Are services accessible to communities at risk, including adolescent girls and young women and key populations, rather than only to people near well-resourced clinics?
UNAIDS has identified reduced funding, patent and licensing barriers, introduction targets below potential supply, and erosion of community HIV services as risks to access. Those barriers can constrain availability even when the medicine itself has promising evidence and manufacturers are preparing supply.
What receiving PrEP may involve
Lenacapavir is prescription PrEP delivered through health services or public programs, not a consumer product to obtain from an unverified online seller. Before using PrEP, a person needs to know their HIV status; ongoing testing is part of safe delivery. WHO has said rapid HIV tests can support long-acting PrEP delivery and recommends them as part of a public-health testing approach. It has also described possible community-based delivery through pharmacies, clinics and telehealth. These are potential delivery routes, not confirmation that every country or provider offers them.
To find out whether the injection is a real option locally, ask a sexual-health or HIV-prevention service, clinician, or national health authority whether lenacapavir is registered and currently being offered, what HIV testing is required, where injections are provided, and whether the cost is covered. If it is not available, a provider can discuss other PrEP methods and prevention choices that are available in that setting.
What is still being studied
The trial findings are striking, but CDC says further research is needed on effectiveness for people who inject drugs; whether lenacapavir can inhibit early viral replication if infection occurs during PrEP use; possible drug resistance; longer-term safety and efficacy; acceptability; and implementation in clinical and community settings. These are questions for ongoing evidence-building, not findings that overturn the results already reported.
CDC also notes that lenacapavir has not been evaluated against injectable cabotegravir in a randomized comparative trial. The available percentages therefore should not be used to rank the two medicines as if they had been tested head to head. Dosing frequency, local delivery and testing arrangements, the populations studied, safety information and personal preference are more appropriate points to discuss with a qualified provider.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
